The latest research suggests that ageing is a cellular energy problem

At a fundamental level, ageing is closely tied to energy. Every cell relies on mitochondria to produce the energy required to maintain structure, repair damage, and renew itself. As cells age, mitochondrial efficiency declines, meaning less energy is available to fully support these renewal processes. In this sense, ageing can be described as a state in which a cell no longer produces sufficient energy to completely maintain and restore itself.

When mitochondrial energy production falls, cells become less efficient. ATP output drops, oxidative stress increases, and the balance between damage and repair begins to shift. Over time, this energetic shortfall contributes to cellular senescence and the gradual loss of tissue function seen across ageing systems. Mitochondrial dysfunction is now widely recognised as one of the central drivers of biological ageing.

Because of this, mitochondrial health has become a major focus in longevity and ageing research. Rather than targeting ageing as a collection of symptoms, many researchers are investigating ways to support the cell’s energy-producing machinery directly.

One area of interest involves signalling peptides that influence mitochondrial function and metabolic regulation. MOTS-c, a mitochondria-encoded peptide, has been shown in studies to play a role in regulating cellular metabolism, improving insulin sensitivity, and enhancing mitochondrial stress responses. Research suggests that MOTS-c levels decline with age, and that restoring its activity in experimental models can improve mitochondrial efficiency and cellular energy handling, particularly under metabolic or age-related stress.

In parallel, significant research attention has been given to SS-31 (elamipretide), a synthetic tetrapeptide designed to target mitochondria directly. SS-31 binds to cardiolipin, a lipid that is essential for maintaining the structure and function of the electron transport chain. By stabilising cardiolipin, SS-31 has been shown to improve electron transport efficiency, reduce excessive reactive oxygen species production, and enhance ATP generation.

In ageing and disease models, SS-31 has demonstrated the ability to rapidly restore mitochondrial bioenergetics, even in tissues with established mitochondrial dysfunction. These effects have been observed in highly energy-dependent tissues such as cardiac muscle, skeletal muscle, and neurons. Importantly, SS-31 has been evaluated in human clinical trials and has received FDA regulatory designations for specific mitochondrial disorders, reflecting its relevance in mitochondrial disease research. However, it is not currently an FDA-approved medication.

Together, research into mitochondrial peptides such as MOTS-c and targeted compounds like SS-31 supports a growing understanding of ageing as an energy-driven process. When cells retain the ability to generate sufficient energy, they are better equipped to maintain function, resist stress, and sustain renewal. Supporting mitochondrial efficiency may therefore be a key mechanism for maintaining cellular health as biological ageing progresses.

These peptides have the potential to redefine how longevity is understood at the cellular level, representing a major scientific development of the past 20 years

References

Frontiers in Physiology – Mitochondrial dysfunction and ageing https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2024.1384966/full

NCBI – Mitochondrial peptides and ageing (MOTS-c) https://pmc.ncbi.nlm.nih.gov/articles/PMC9057581/

Aging (Albany NY) – MOTS-c and mitochondrial regulation https://www.aging-us.com/article/101463/text

NCBI – SS-31 restores mitochondrial bioenergetics in aged models https://pmc.ncbi.nlm.nih.gov/articles/PMC3772966/

Click for Mots-c

Click for SS-31